1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Drugs In Development, 2022, provides an overview of the Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Vancomycin resistant staphylococcus infection is a condition caused by bacteria (germs). This infection occurs when bacteria, called Staphylococcus aureus or Staph, becomes resistant (not killed) to the antibiotic medicine vancomycin. Risk factors include taking strong antibiotics the wrong way may cause the bacteria to develop resistance to the antibiotics, weak immune system and staying in the hospital too long. Symptoms include fever, chills, cough, chest pain, trouble breathing, and a fast heartbeat.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 2, 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 2 molecules, respectively.
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Overview
- Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Companies Involved in Therapeutics Development
- Amprologix Ltd
- CrystalGenomics Inc
- Destiny Pharma Plc
- Lysimmune BioScience
- Sano Chemicals Inc
- TAXIS Pharmaceuticals Inc
- TGV-Inhalonix Inc
- Therapeutic Systems Research Laboratories Inc
- Wockhardt Ltd
- Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Drug Profiles
- APY-281 - Drug Profile
- Product Description
- Mechanism Of Action
- CG-549 - Drug Profile
- Product Description
- Mechanism Of Action
- Epidermicin NI-01 - Drug Profile
- Product Description
- Mechanism Of Action
- exeporfinium chloride - Drug Profile
- Product Description
- Mechanism Of Action
- LI-03 - Drug Profile
- Product Description
- Mechanism Of Action
- Mul-1867 - Drug Profile
- Product Description
- Mechanism Of Action
- MUT-001 - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecule for Gram-Positive Bacterial Infections - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecule to Inhibit crtN for Staphylococcus aureus Infections - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecule to Inhibit PBP2 for Gram-Positive Bacterial Infections - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecule to Inhibit PBP2a for Gram-Positive Bacterial Infections - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules for Gram Positive Bacterial Infections - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules for MRSA and VRSA Infections - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Inhibit Methionine tRNA Ligase for Gram Positive Bacterial Infections - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Inhibit Oxacillinase for Gram-Positive Bacterial Infections - Drug Profile
- Product Description
- Mechanism Of Action
- TXA-709 - Drug Profile
- Product Description
- Mechanism Of Action
- WCK-4086 - Drug Profile
- Product Description
- Mechanism Of Action
- Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Dormant Projects
- Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Discontinued Products
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Amprologix Ltd, 2022
- Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by CrystalGenomics Inc, 2022
- Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Destiny Pharma Plc, 2022
- Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Lysimmune BioScience, 2022
- Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Sano Chemicals Inc, 2022
- Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by TAXIS Pharmaceuticals Inc, 2022
- Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by TGV-Inhalonix Inc, 2022
- Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Therapeutic Systems Research Laboratories Inc, 2022
- Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Wockhardt Ltd, 2022
- Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Dormant Projects, 2022
- Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Discontinued Products, 2022
- Number of Products under Development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Amprologix Ltd
- CrystalGenomics Inc
- Destiny Pharma Plc
- Lysimmune BioScience
- Sano Chemicals Inc
- TAXIS Pharmaceuticals Inc
- TGV-Inhalonix Inc
- Therapeutic Systems Research Laboratories Inc
- Wockhardt Ltd
